Abbott India Limited vs GlaxoSmithKline Pharmaceuticals Limited
An objective side-by-side of ABBOTINDIA and GLAXO, both in Pharmaceuticals - Multinational: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: ABBOTINDIA Dec 2025 · GLAXO Jun 2026
At a glance
- Abbott India Limited is the larger company by market value, about 1.2 times the size of GlaxoSmithKline Pharmaceuticals Limited.
- On trailing earnings, Abbott India Limited trades at the lower P/E (39.6 against 45.4).
- GlaxoSmithKline Pharmaceuticals Limited earns the higher return on equity (47.1% against 30.3%).
- Over the past year the share prices returned -12.8% (ABBOTINDIA) and +3.9% (GLAXO).
| Metric | Abbott India ABBOTINDIA |
GlaxoSmithKline Pharmaceuticals GLAXO |
|---|---|---|
| Size and price | ||
| Market cap | ₹57,288 Cr | ₹48,499 Cr |
| Share price | ₹26,960 | ₹2,863 |
| Valuation | ||
| P/E | 39.64 | 45.42 |
| P/B | 12.00 | 21.39 |
| EV/EBITDA | 33.34 | 30.08 |
| PEG | — | 2.52 |
| Dividend yield | — | 2.0% |
| Profitability | ||
| ROE | 30.3% | 47.1% |
| ROCE | 45.0% | 61.0% |
| Operating margin | 26.4% | 40.8% |
| Sales (TTM) | ₹6,524 Cr | ₹3,955 Cr |
| Net profit (TTM) | ₹1,445 Cr | ₹1,068 Cr |
| Growth | ||
| Latest quarter sales YoY | — | +16.6% |
| Latest quarter profit YoY | — | +15.7% |
| Sales CAGR 3Y | — | +6.0% |
| Profit CAGR 3Y | — | +18.0% |
| Sales CAGR 5Y | — | +5.0% |
| Profit CAGR 5Y | — | +15.0% |
| Financial strength | ||
| Debt/Equity | 0.04 | 0.01 |
| Interest cover | — | 420.19 |
| Ownership | ||
| Promoter holding | 75.0% | 75.0% |
| Promoter change (4 qtrs) | +0.00 pp | +0.00 pp |
| Price performance | ||
| Return 1M | +3.22% | -4.56% |
| Return 3M | +3.43% | +21.15% |
| Return 1Y | -12.78% | +3.91% |
| Return YTD | -7.11% | +15.74% |
| Technical condition | ||
| Technical score | 75 | 55 |
| RS rating (1-99) | 50.00 | 71.00 |
| % vs 200-DMA | -0.07% | +14.50% |
| RSI (14) | 57.51 | 51.54 |
| % from 52-week high | -14.02% | -8.26% |
